Alemtuzumab-based therapy for Secondary Malignant Histiocytosis arising from Pre-B-ALL. Leuk Res Rep 2018;9:5-8
Date
12/22/2017Pubmed ID
29264111Pubmed Central ID
PMC5726878DOI
10.1016/j.lrr.2017.11.003Scopus ID
2-s2.0-85037688019 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
•Secondary Malignant Histiocytosis (SMH) is an exceedingly rare, life-threatening condition that invariably occurs in the presence of an underlying monoclonal hematologic disorder. Prognosis of SMH remains dismal and there is no established treatment. •We report a case of a patient who developed SMH during induction chemotherapy for his underlying pre-B-ALL, that caused persistently high fevers and was only diagnosed by a marrow while cytopenic in phase 2 induction. He was treated with alemtuzumab-based therapy that reduced the histiocytic infiltration of the bone marrow from 80% to 15% and made him eligible to undergo T-cell replete allogeneic stem transplantation from his sibling. •This report is the first to highlight the role of alemtuzumab, an anti-CD52 monoclonal antibody, in clonal disorders originating from transdifferentiation. •The alemtuzumab-based regimen should be reserved only for carefully selected allogeneic transplant patients.
